JMP Securities maintains Arbutus Biopharma at 'market outperform' with a price target of $4.00

  • Investing.com
JMP Securities maintains Arbutus Biopharma at 'market outperform' with a price target of $4.00

An analyst from JMP Securities maintained Arbutus Biopharma (NASDAQ: ABUS ) at 'market outperform' with a price target of $4.00 from a prior price target of %currency%%price%.

Prior to this rating, Arbutus Biopharma had 4 buy ratings, 1 hold ratings, and 0 sell ratings.

For consensus analyst estimates and price targets on Arbutus Biopharma, click here. For more news on Arbutus Biopharma, click here.

Arbutus Biopharma's stock price closed at $2.200. They are up 9.45% in the last month and down -3.080% in the last 12 months.

According to Investing Pro, Arbutus Biopharma's fair value is $2.329, an upside of 5.867%. Arbutus Biopharma's fair value comes with a medium degree of uncertainty, according to InvestingPro.

Check out Arbutus Biopharma's recent earnings performance and financials here.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100

Related Articles